<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:media="http://search.yahoo.com/mrss/"
>
<channel>
		<title>CADTH: CDR News</title>
		<description></description>
		<link>http://www.cadth.ca/index.php/en</link>
		<language>en</language>
		<lastBuildDate>Fri, 12 Mar 2010 17:09:15 -0500</lastBuildDate>
		<item>
    <title><![CDATA[Consultations on Patient Input]]></title>
    <description><![CDATA[]]></description>
    <pubDate>Thu, 10 Dec 2009 00:00:00 -0500</pubDate>
        <link>http://www.cadth.ca/index.php/en/cdr/cdr-update/cdr-update-issue-63</link>
</item>
<item>
    <title><![CDATA[New Pilot Project: Therapeutic Reviews]]></title>
    <description><![CDATA[<p>On December 7, 2009 the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a pilot project for conducting a concurrent review of a CDR submission(s) and a therapeutic review of the same drug class or category as the CDR submission.</p>
<h2>What is a therapeutic review?</h2>
<p>A
therapeutic review is a review of the most recent evidence available in the
public domain regarding a single drug, a drug class, or a drug category.
Generally, these are drugs, drug classes, or drug categories that have been
available in the marketplace for some time. The scope and depth of the reviews
will be determined by the jurisdictions and CADTH. The final outputs of the
CADTH therapeutic reviews will include either recommendations, advice, or a
report and conclusions.</p>
<h2>Why is CADTH undertaking a therapeutic
review pilot project?</h2>
<p>The
need for therapeutic reviews at the time that formulary decisions are being
made has been identified as a need by participating drug plans and expert
advisory committees for some time. Therapeutic reviews are seen as an important tool in the overall
recommendation and policy decision-making process. In addition to making
listing decisions based on efficacy, safety, and cost-effectiveness analyses of
available information, drug plans also consider the existing coverage policies
of therapeutically related drugs. To this end, a working group comprising members from the <a href="http://www.cadth.ca/index.php/en/cdr/committees/acp">Advisory Committee
on Pharmaceuticals</a>, the <a href="http://www.cadth.ca/index.php/en/compus/advis-committees/cac">COMPUS
Advisory Committee</a>, and CADTH staff has
developed a framework for therapeutic reviews conducted concurrently with
formulary submissions. The purpose of the pilot project is to test and to make
enhancements to the framework.&nbsp;</p>
<h2>Will affected manufacturers have a role in the therapeutic review pilot project?</h2>
<p>Manufacturers that have products included in the
therapeutic review pilot project will be apprised directly and will be invited
to provide input and comments during specific phases of the therapeutic review
process.</p>
<h2 style="margin-left: 0.25in; text-indent: -0.25in;">What
are the next steps in the therapeutic review pilot project?&nbsp;</h2>
<ul>
<li>A
more detailed description of the therapeutic review pilot project will be
posted in the near future.</li>
<li>On
completion, the therapeutic review pilot project will be evaluated. The
findings from the evaluation will be used to make changes and improvements to
the requirements and process for conducting therapeutic reviews.</li>
</ul>
<ul>
<li>The
revised process for conducting therapeutic reviews will be posted for
stakeholder feedback (after the pilot project is completed), and relevant
feedback will be used to further enhance the process.</li>
</ul>
<p>We
can be contacted at <a href="mailto:cadthfeedback@cadth.ca">cadthfeedback@cadth.ca</a>.&nbsp;</p>]]></description>
    <pubDate>Mon, 07 Dec 2009 00:00:00 -0500</pubDate>
        <link>http://www.cadth.ca/index.php/en/cdr/cdr-news/2009/12/7/199</link>
</item>
</channel>
</rss>